A single nucleotide polymorphism in the Mdm2 promoter and risk of sepsis.
暂无分享,去创建一个
[1] M. Netea,et al. Gender differences in the innate immune response and vascular reactivity following the administration of endotoxin to human volunteers* , 2007, Critical care medicine.
[2] Doron Lancet,et al. Haplotype structure and selection of the MDM2 oncogene in humans , 2007, Proceedings of the National Academy of Sciences.
[3] S. Calvano,et al. GENDER INFLUENCES IN VIVO HUMAN RESPONSES TO ENDOTOXIN , 2006, Shock.
[4] A. Levine,et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. , 2006, Cancer research.
[5] C. Roussos,et al. Early apoptosis of blood monocytes in the septic host: is it a mechanism of protection in the event of septic shock? , 2006, Critical care.
[6] W. Su,et al. Euthyroid sick syndrome in trauma patients with severe inflammatory response syndrome. , 2006, Chinese journal of traumatology = Zhonghua chuang shang za zhi.
[7] D. Eccles,et al. Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers , 2006, BMC Cancer.
[8] John Savill,et al. Resolution of inflammation: the beginning programs the end , 2005, Nature Immunology.
[9] C. Coopersmith,et al. Prevention of lymphocyte apoptosis--a potential treatment of sepsis? , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] John D. Storey,et al. A network-based analysis of systemic inflammation in humans , 2005, Nature.
[11] E. Abraham,et al. GENETIC POLYMORPHISMS AND SEPSIS , 2005, Shock.
[12] A. Levine,et al. A Chromatin-associated and Transcriptionally Inactive p53-Mdm2 Complex Occurs in mdm2 SNP309 Homozygous Cells* , 2005, Journal of Biological Chemistry.
[13] E. Hurt,et al. Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation. , 2005, Cancer research.
[14] D. Green,et al. Regulation of arthritis by p53: critical role of adaptive immunity. , 2005, Arthritis and rheumatism.
[15] A. Levine,et al. A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans , 2004, Cell.
[16] F. Finkelman,et al. Bacterial Lipoprotein Delays Apoptosis in Human Neutrophils through Inhibition of Caspase-3 Activity: Regulatory Roles for CD14 and TLR-2 , 2004, The Journal of Immunology.
[17] N. Maca-Meyer,et al. Bench-to-bedside review: Understanding genetic predisposition to sepsis , 2004, Critical care.
[18] U. Moll,et al. The MDM2-p53 interaction. , 2003, Molecular cancer research : MCR.
[19] Guillermina Lozano,et al. MDM2, an introduction. , 2003, Molecular cancer research : MCR.
[20] K. Walley,et al. Genetic polymorphisms in sepsis and septic shock: role in prognosis and potential for therapy. , 2003, Chest.
[21] J. Blaydes,et al. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells. , 2003, Cancer research.
[22] M. Levy,et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference , 2003, Intensive care medicine.
[23] N. Risch,et al. The importance of race and ethnic background in biomedical research and clinical practice. , 2003, The New England journal of medicine.
[24] José A Fernández,et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective , 2003, Nature Medicine.
[25] M. Cutolo,et al. Synovial fluid from patients with rheumatoid arthritis inhibits neutrophil apoptosis: role of adenosine and proinflammatory cytokines. , 2002, Rheumatology.
[26] John David,et al. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: Regulatory role in the innate immune response , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[27] I. Chaudry,et al. Gender differences in the inflammatory response and survival following haemorrhage and subsequent sepsis. , 2001, Cytokine.
[28] R. Hotchkiss,et al. p53-Dependent and -Independent Pathways of Apoptotic Cell Death in Sepsis1 , 2000, The Journal of Immunology.
[29] Hsiao-Huei Wu,et al. MDM2--master regulator of the p53 tumor suppressor protein. , 2000, Gene.
[30] G. Hannon,et al. A Proinflammatory Cytokine Inhibits P53 Tumor Suppressor Activity , 1999, The Journal of experimental medicine.
[31] K. Kyokane,et al. Increased mucosal production of granulocyte colony‐stimulating factor is related to a delay in neutrophil apoptosis in Inflammatory Bowel disease , 1999, Journal of gastroenterology and hepatology.
[32] H. Samuels,et al. Regulation of the mdm2 Oncogene by Thyroid Hormone Receptor , 1999, Molecular and Cellular Biology.
[33] J. Vincent,et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure , 1996, Intensive Care Medicine.
[34] M. Langer,et al. The Italian SEPSIS study: Preliminary results on the incidence and evolution of SIRS, sepsis, severe sepsis and septic shock , 1995, Intensive Care Medicine.
[35] S. McClave,et al. The Acute Physiology and Chronic Health Evaluation II classification system is a valid marker for physiologic stress in the critically ill patient , 1993, Critical care medicine.
[36] T. Akahoshi,et al. Prevention of neutrophil apoptosis by monosodium urate crystals , 2005, Rheumatology International.
[37] S. Hussain,et al. Nitric oxide and p53 in cancer‐prone chronic inflammation and oxyradical overload disease , 2004, Environmental and molecular mutagenesis.
[38] D. Green,et al. Regulation of joint destruction and inflammation by p53 in collagen-induced arthritis. , 2002, The American journal of pathology.